Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
EMERYVILLE, Calif., Sept. 11, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees stock options to purchase an aggregate of 15,450 shares of the company’s common stock, at a per share exercise price of $20.77, the closing trading price on September 11, 2017, and restricted stock units to acquire 7,725 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRITM (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment, and ADS-4101, a high-dose, modified-release lacosamide in Phase 1 clinical development for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas’s licensed assets are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
